Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Five-period, Balanced Crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag Powder for Oral Suspension (PfOS) Formulation Relative to the Commercial 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in Healthy Adult Subjects
Brief Summary: This is a randomized, open-label, five-period, balanced crossover study conducted in approximately 40 healthy adult subjects enrolled at one study center in the USA. Subjects receive five eltrombopag treatments: tablet fasted, Powder for Oral Suspension (PfOS) fasted, PfOS with a high calcium meal, PfOS 2 hours prior to a high calcium meal, and PfOS 2 hours after a high calcium meal, and each treatment is a single 25 mg dose. There is a 10 to 14 day washout between periods, and between the last dose of study drug and the follow-up visit. During each treatment period, subjects undergo serial PK sampling over 72 hours for measurement of plasma eltrombopag concentrations. Safety is assessed by vital signs, clinical safety laboratory assessments, and adverse events reporting.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: 750 mcg AMG 531; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Arm Label: Placebo Part B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Part A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 500 mcg AMG 531; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Arm Label: 750 mcg AMG531 Part B; Type: ACTIVE_COMPARATOR; Interventions: Biological: AMG 531 | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): 500 mcg AMG 531, 750 mcg AMG 531, 750 mcg AMG531 Part B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Part A, Placebo Part B
C: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW
D: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm E; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm A; Type: OTHER; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Arm B, Arm C, Arm D, Arm E

Answer: D